Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Morgensztern

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
Journal of Thoracic Disease|October 22, 2019
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49Daniel Morgensztern
Cancer|February 29, 2024
The expanding role of circulating tumor DNA in resectable non-small cell lung cancerDaniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
A roundup of recently published articles relevant to thoracic oncologyDaniel Morgensztern, Ramaswamy Govindan
Clinical Lung Cancer|January 1, 2014
Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer MeetingDaniel Morgensztern, Ramaswamy Govindan
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Adjuvant chemotherapy for lung cancer: cisplatin doublets only?Daniel Morgensztern, Ramaswamy Govindan
Translational Lung Cancer Research|February 2, 2019
Role of immune checkpoint blockers in patients with <i>EGFR</i> mutationJeffrey Ward, Daniel Morgensztern
Clinical Lung Cancer|September 3, 2011
Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histologyDaniel Morgensztern, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2021
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After ChemoradiationDaniel Morgensztern, Ramaswamy Govindan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Is there a role for cetuximab in non small cell lung cancer?Daniel Morgensztern, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
Best of the month: A round up of articles published in recent monthsDaniel Morgensztern, Ramaswamy Govindan
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
Journal of Thoracic Disease|October 22, 2019
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49Daniel Morgensztern
Cancer|February 29, 2024
The expanding role of circulating tumor DNA in resectable non-small cell lung cancerDaniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
A roundup of recently published articles relevant to thoracic oncologyDaniel Morgensztern, Ramaswamy Govindan
Clinical Lung Cancer|January 1, 2014
Summary report from the 13(th) Annual Targeted Therapies of the Treatment of Lung Cancer MeetingDaniel Morgensztern, Ramaswamy Govindan
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Adjuvant chemotherapy for lung cancer: cisplatin doublets only?Daniel Morgensztern, Ramaswamy Govindan
Translational Lung Cancer Research|February 2, 2019
Role of immune checkpoint blockers in patients with <i>EGFR</i> mutationJeffrey Ward, Daniel Morgensztern
Clinical Lung Cancer|September 3, 2011
Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histologyDaniel Morgensztern, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2021
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After ChemoradiationDaniel Morgensztern, Ramaswamy Govindan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Is there a role for cetuximab in non small cell lung cancer?Daniel Morgensztern, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
Best of the month: A round up of articles published in recent monthsDaniel Morgensztern, Ramaswamy Govindan
Pageof 19